Trial ID or NCT#

NCT02161406

Status

recruiting iconRECRUITING

Purpose

The study hypothesis is that SC abatacept is safe and shows evidence of efficacy (improvement in modified Rodnan score [mRSS]) in patients with diffuse cutaneous systemic sclerosis (dcScc) compared to matching placebo.

Contact us to find out if this trial is right for you.

CONTACT

Saranya Nandagopal